TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,469,316 | +83.3% | 178,749 | +71.9% | 0.00% | – |
| Q1 2024 | $801,686 | -10.3% | 103,980 | +4.6% | 0.00% | – |
| Q4 2023 | $893,831 | +0.6% | 99,425 | 0.0% | 0.00% | – |
| Q3 2023 | $888,860 | -55.4% | 99,425 | +12.3% | 0.00% | -100.0% |
| Q2 2023 | $1,991,378 | 0.0% | 88,545 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,991,378 | +48.9% | 88,545 | +39.3% | 0.00% | 0.0% |
| Q4 2022 | $1,337,045 | -99.9% | 63,578 | +1.8% | 0.00% | 0.0% |
| Q3 2022 | $1,538,177,000 | -4.1% | 62,426 | -5.7% | 0.00% | 0.0% |
| Q2 2022 | $1,603,177,000 | -7.4% | 66,165 | -1.5% | 0.00% | 0.0% |
| Q1 2022 | $1,731,255,000 | -11.7% | 67,181 | +6.3% | 0.00% | 0.0% |
| Q4 2021 | $1,961,355,000 | +56.2% | 63,188 | +22.0% | 0.00% | 0.0% |
| Q3 2021 | $1,255,543,000 | +60.7% | 51,775 | -3.3% | 0.00% | – |
| Q2 2021 | $781,353,000 | -36.6% | 53,554 | +8.4% | 0.00% | -100.0% |
| Q1 2021 | $1,233,143,000 | +17.0% | 49,385 | +27.7% | 0.00% | – |
| Q4 2020 | $1,054,359,000 | – | 38,685 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,026,300 | $21,583 | 6.98% |
| Deep Track Capital, LP | 4,582,000 | $96,359,460 | 4.05% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 379,019 | $7,963,189 | 2.46% |
| ARMISTICE CAPITAL, LLC | 6,412,000 | $134,844,360 | 2.35% |
| GREAT POINT PARTNERS LLC | 475,000 | $9,989,250 | 1.96% |
| RA Capital Management | 3,984,681 | $83,797,841 | 1.70% |
| MPM BioImpact LLC | 281,711 | $5,924,382 | 1.54% |
| HighVista Strategies LLC | 121,834 | $2,562,169 | 1.52% |
| Kynam Capital Management, LP | 418,099 | $8,792,622 | 1.35% |
| SECTORAL ASSET MANAGEMENT INC | 292,320 | $6,147,490 | 1.19% |